Fragment Based Drug Discovery - Niche or Mainstream?

Wed3  Sep02:30pm(30 mins)
Charter 2


Over the past decade, fragment-based drug discovery (FBDD) has become a widely accepted tool across industry and academia. At Astex, we have now successfully applied our fragment-based screening approach, PyramidTM, to over 30 targets from a broad range of protein classes. Typically the small molecule fragments we use have MW ~200 and binding affinities between mM weak uM. Subsequently, in the fragments-to-leads stage a detailed structural understanding of the binding interactions between the fragment and its target protein utilizing X-ray crystallography is critical. We monitor the Ligand Efficiency (LE) throughout the optimisation in order to control the chemical properties of the final clinical candidates. This presentation will start with a general overview of the techniques associated with fragment based drug discovery before reviewing specific examples of Astex's FBDD programmes leading to development candidates.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021